At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
In Brief
A Phase 3 clinical trial evaluating magnesium sulfate for Cerebral Palsy and 4 related conditions. Completed, enrolled 2,136 participants across 17 sites.
Detailed Summary
As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus (24 to 31 weeks out of 40) will reduce the rate of death or moderate to severe CP in the children at 2 years. The children receive ultrasounds of their brains as infants and attend three follow-up visits over two years to assess their health and development.